During the past decade, Cancer and Hematology Centers of Western Michigan conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 17 clinical trials were completed, i.e. on average, 47.2% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 9 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cancer and Hematology Centers of Western Michigan" #1 sponsor was "Bristol-Myers Squibb" with 5 trials, followed by "Merck Sharp & Dohme LLC" with 4 trials sponsored, "Novartis Pharmaceuticals" with 4 trials sponsored, "Pfizer" with 4 trials sponsored and "Celgene" with 4 trials sponsored. Other sponsors include 32 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cancer and Hematology Centers of Western Michigan" #1 collaborator was "Eisai Inc." with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Bionomics Limited" with 1 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Cancer and Hematology Centers of Western Michigan" are "Breast Cancer" (5 trials), "Multiple Myeloma" (4 trials), "Carcinoma, Renal Cell" (3 trials), "Myelodysplastic Syndromes" (3 trials) and "Acute Myeloid Leukemia" (2 trials). Many other conditions were trialed in "Cancer and Hematology Centers of Western Michigan" in a lesser frequency.

Most popular intervention types in "Cancer and Hematology Centers of Western Michigan" are "Drug" (49 trials), "Biological" (6 trials), "Other" (6 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Dexamethasone" (5 trials), "Docetaxel" (5 trials), "Gemcitabine" (5 trials), "Nivolumab" (5 trials) and "Pemetrexed" (4 trials). Other intervention names were less common.

The vast majority of trials in "Cancer and Hematology Centers of Western Michigan" are 52 trials for "All" genders, 3 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Cancer and Hematology Centers of Western Michigan". undefined are not yet recruiting, 10 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Cancer and Hematology Centers of Western Michigan, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Cancer and Hematology Centers of Western Michigan, 8 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".

Cancer and Hematology Centers of Western Michigan has several departments that took part in Clinical trials: "Lacks Cancer Center at Saint Mary's Health Care" - 110 trials, "Cancer and Hematology Centers of Western Michigan - Norton Shores" - 97 trials, "South Texas Accelerated Research Therapeutics Midwest" - 4 trials